Skip to main content
OpenTrials
Completed

NCT Number: NCT05498649

Performance of Dailies Total1® Contact Lenses for Astigmatism in Symptomatic Habitual Reusable Toric Lens Wearers

To subjectively evaluate Dailies Total1® contact lenses for astigmatism (DT1fA) performance compared to other common weekly/monthly contact lenses in symptomatic patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–38 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Scripps Poway Eyecare & Optometry

San Diego, California, 92131, United States

About this study

This study is a single site, prospective, subject-masked, observational study of the subjective performance of DT1fA in symptomatic patients. Subjects will be assessed at a screening visit, and 2 follow-up visits. Clinical evaluations will include measurement of visual acuity, manifest refraction, and patient questionnaires.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

Inclusion criteria

  • Willing and able to provide informed consent
  • Adult (18-38 years of age)
  • Adapted and optimized current reusable soft toric lens wearer who has at least 3 months of wearing experience, and typically wears lenses every day, or at least 5 days per week, ≥10 hours per day
  • Prescription needs with sphere and cylinder values that can be appropriately fit with current available parameters in the Dailies Total1® Contact lenses for Astigmatism product line
  • Vision correctable to 20/25 Snellen (0.1 logMAR) or better in each eye at 6m
  • Willing to wear lenses every day or at least 5 days per week, 10 or more hours per day and attend all study visits and follow instructions
  • CLDEQ-8 minimum score of 12

Exclusion criteria

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Ocular anterior segment infection, inflammation, abnormality, or active disease including diagnosed dry eye, that would contraindicate contact lens wear
  • Use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the Investigator
  • Monocular (only 1 eye with functional vision) or fit with only 1 lens
  • Fitted with monovision
  • Prior Refractive Surgery
  • History of herpetic keratitis, ocular surgery, or irregular cornea
  • Pregnant or lactating

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Treatment and study plan

DT1fA

Device

DT1fA contact lenses

Primary outcomes

  1. Contact Lens Dry Eye Questionnaire (CLDEQ-8) Score

    Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)

    A series of 8 questions that ask participants to rate eye discomfort, eye dryness, and blurry vision on a frequency scale (0 Never, 1 Rarely, 2 Sometimes, 3 Frequently, 4 Constantly) and an intensity scale (0 Never, 1 not intense to 5 Very Intense). Scores on individual questions are added together to determine a total score. Higher values indicate worse outcomes. The minimum score is 1 and the maximum score is 37.

Other outcomes

  1. The Percentage of Participants That Reported Little to no Intensity of Eye Discomfort at Baseline and 2 Weeks of DT1fA Wear for End of Day (EOD)

    Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)

    Participants were asked to rate end of day discomfort intensity (0 Never, 1 not intense to 5 Very Intense). Higher values indicate worse outcomes.

  2. The Percentage of Participants That Reported Little to no Intensity of Eye Dryness at Baseline and 2 Weeks of DT1fA Wear for End of Day (EOD)

    Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)

    Participants were asked to rate end of day dryness intensity (0 Never, 1 not intense to 5 Very Intense). Higher values indicate worse outcomes.

  3. The Percentage of Participants That Reported Little to no Noticeable Change Between Clear to Blurry or Foggy Vision at Baseline and 2 Weeks of DT1fA Wear for End of Day (EOD)

    Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)

    Participants were asked to rate noticeable change between clear to blurry or foggy vision (0 Never, 1 not intense to 5 Very Intense). Higher values indicate worse outcomes.

  4. Hours of Comfortable Wear

    Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)

  5. Vision Stability

    Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)

  6. Binocular Contact Lens Corrected Visual Acuity at Distance (6m)

    Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)

Sponsors and collaborators

Lead sponsor

Keith Wan

Other

Collaborators

  • Sengi

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Aug 12, 2022
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.